drugset / Trial / NCT07796100
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.
Timeline
- Start
- 2026-12-31
- Primary completion
- 2030-06-30
- Completion
- 2031-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atezolizumab | Monoclonal antibody | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cistplatin | Unknown | — | — |
| Comparator | Durvalumab | Monoclonal antibody | — | — |
| Comparator | Etoposide | Small molecule | — | — |
| Comparator | Lurbinectedin | Other / unclassified | — | — |
| Subject | ZL-1310 | Unknown | — | — |